Expression and Clinical Prognostic Value of Platelet NLRP3 in Acute Coronary Syndrome
Received 4 August 2020
Accepted for publication 9 September 2020
Published 9 October 2020 Volume 2020:13 Pages 791—802
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Scott Fraser
Huitong Peng,1 Hongyi Wu,2 Ge Zhang,1 Wei Zhang,1 Yifan Guo,2 Lin Chang,1 She Chen,1 Ruyi Xue,3 Si Zhang1
1Department of Biochemistry and Molecular Biology, NHC Key Laboratory of Glycoconjugates Research, School of Basic Medical Sciences, Fudan University, Shanghai, People’s Republic of China; 2Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China; 3Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China
Correspondence: Ruyi Xue
Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, No. 160, Feng Lin Road, Xuhui, Shanghai, People’s Republic of China
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, No. 130, Dong’an Road, Xuhui, Shanghai, People’s Republic of China
Tel +86 138 1709 2601
Purpose: Little is known about the relationship between the level of platelet NOD-like receptor protein 3 (NLRP3) and the severity of acute coronary syndrome (ACS) or the prognostic value of platelet NLRP3 for percutaneous coronary intervention (PCI).
Methods: Platelets collected from 25 healthy subjects, 23 patients with stable angina pectoris (SAP), and 72 patients with ACS were analyzed by Western blotting and real-time fluorescence quantitative PCR (qPCR). A total of 152 patients with ACS who had undergone PCI were included in this study to evaluate the prognostic value of platelet NLRP3.
Results: The levels of platelet NLRP3 in both the healthy and SAP groups were clearly lower than in the ACS group (P< 0.001). According to the Pearson correlation analysis, the expression of platelet NLRP3 was closely related to the mean platelet volume (MPV), left ventricular ejection fraction (LVEF), the Gensini score, and the Global Registry of Acute Coronary Events (GRACE) score (all P< 0.001). Multivariate logistic regression analysis identified NLRP3 as an independent risk factor for adverse cardiovascular events (ACEs) after PCI (P=0.004). The proportion of patients with high NLPR3 expression (the NLRP3-high group) remaining free of adverse events for 3 years was remarkably lower than that in patients with low NLPR3 expression (the NLRP3-low group; P=0.024). The NLRP3-high group had a significantly higher proportion of patients with interleukin-1β–expressing (20.4%± 6.1%) platelets than the NLRP3-low group (10.7%± 3.5%, P< 0.001). Moreover, the NLRP3-high group exhibited higher platelet activity, as indicated by increased PAC-1 binding and CD62P expression, compared with the NLRP3-low group (P< 0.001).
Conclusion: These results indicated that platelet NLRP3 was a novel potential prognostic factor for patients with ACS that underwent PCI.
Keywords: platelet NLRP3, acute coronary syndromes, percutaneous coronary intervention, inflammation, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]